Difficulty: Medium
Average Score: 84%
Practice
Use of the following antimalarial drug carrys high risk of adverse effect in subjects with G-6-PD deficiency.
Correct answer
C
Rationale
In the context of chemotherapy drugs and their potential adverse effects, the correct answer to the question is option C) Primaquine. Primaquine is an antimalarial drug known to cause severe hemolysis in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. G-6-PD deficiency is a genetic condition that affects red blood cells, leading to their destruction when exposed to certain triggers like primaquine. This adverse effect is due to the drug's ability to induce oxidative stress in G-6-PD deficient individuals, resulting in hemolytic anemia.
Regarding the other options:
A) Pyrimethamine is primarily used to treat malaria and toxoplasmosis, but it is not specifically associated with adverse effects in G-6-PD deficient individuals.
B) Artemisinin is a key component of artemisinin-based combination therapies for malaria. While it is important to consider G-6-PD status in malaria treatment, artemisinin itself is not linked to significant adverse effects in G-6-PD deficient individuals.
D) Mefloquine is another antimalarial drug, but its use is not specifically contraindicated in individuals with G-6-PD deficiency.
Educationally, understanding the interactions between specific drugs and genetic conditions like G-6-PD deficiency is crucial for healthcare professionals involved in prescribing medications, especially in populations where such genetic traits are more prevalent. This knowledge helps in ensuring safe and effective treatment strategies, minimizing adverse effects, and optimizing patient outcomes.
Regarding the other options:
A) Pyrimethamine is primarily used to treat malaria and toxoplasmosis, but it is not specifically associated with adverse effects in G-6-PD deficient individuals.
B) Artemisinin is a key component of artemisinin-based combination therapies for malaria. While it is important to consider G-6-PD status in malaria treatment, artemisinin itself is not linked to significant adverse effects in G-6-PD deficient individuals.
D) Mefloquine is another antimalarial drug, but its use is not specifically contraindicated in individuals with G-6-PD deficiency.
Educationally, understanding the interactions between specific drugs and genetic conditions like G-6-PD deficiency is crucial for healthcare professionals involved in prescribing medications, especially in populations where such genetic traits are more prevalent. This knowledge helps in ensuring safe and effective treatment strategies, minimizing adverse effects, and optimizing patient outcomes.